EP3349741A1 - Composition having antiviral effect - Google Patents
Composition having antiviral effectInfo
- Publication number
- EP3349741A1 EP3349741A1 EP16767247.6A EP16767247A EP3349741A1 EP 3349741 A1 EP3349741 A1 EP 3349741A1 EP 16767247 A EP16767247 A EP 16767247A EP 3349741 A1 EP3349741 A1 EP 3349741A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- viral infection
- benzocaine
- benzalkonium chloride
- tyrothricin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising rothricin, benzalkonium chloride, and / or benzocaine for use in anti-viral therapy or in the treatment of a viral infection.
- Viruses and bacteria are the causative agents of very common acute pharyngitis.
- Dorithricin ® throat tablets Classic These are usually used with the antiseptic and antibacterial agents contained therein for clinically effective relief of the typical pharyngitis symptoms swallowing pain and pharyngeal redness.
- Tyrothricin is a mixture of various antibacterial linear and cyclic polypeptides from the groups of gramicidines and tyrocidines. They are endotoxin-like formed by the anaerobic spore-forming Bacillus aneurinolyticus (Syn. Bacillus brevis). The range of action includes predominantly Gram-positive bacteria, but also some Gram-negative bacteria and various types of fungi, such as Candida albicans. Tyrothricin contains 50 to 70% tyrocidines and 25 to 50% gramicidines, which together make up at least 85% of the active substance. In addition, other structurally related polypeptides are present in small quantities.
- Benzalkonium chloride is a mixture of alkylbenzyldimethylammonium chlorides whose alkyl moiety consists of C8 to C18 chains. It generally has disinfecting and preserving effect and is effective against bacteria, fungi, yeasts and algae (to a lesser extent also antiviral).
- Benzocaine (4-Aminobenzoeklathylester) is a local anesthetic and is mainly for local pain therapy of the skin and mucous membranes, such as in the mouth and throat area, as well as medicines for colds, antitussive preparations, painkillers such as solutions or lozenges in cervical, gastric and Teething problems, astringents, application.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising rothricin, benzalkonium chloride, and / or benzocaine for use in anti-viral therapy or in the treatment of a viral infection.
- the composition comprises all three active ingredients in combination.
- Figure 1. - 4 Percent inhibition of the viral activity of viruses HR14, H1N1 and RSV by variously diluted solutions of Dorithricin®.
- Fig.l synergistic, antiviral effect of all 3 active ingredients tyrothricin, benzalkonium chloride and benzocaine in combination in increasing dilution. Synergistic effect is demonstrated in comparison to Fig. 2-4.
- Fig.2 weak antiviral effect of tyrothricin alone in increasing dilution.
- Fig.3 very weak antiviral effect of benzalkonium chloride alone in increasing dilution.
- Tyrothricin as an antibiotic is classified as active against bacteria, benzalkonium chloride and benzocaine are classified as analgesics for pain acting (1-4).
- the present invention thus relates to a pharmaceutical composition
- a pharmaceutical composition comprising
- composition of the present invention may comprise, consist of, or consist essentially of the above-mentioned active ingredients.
- the phrase "consists essentially of” means that the pharmaceutical composition contains these ingredients as effective ingredients. However, it may further contain one or more solvents, adjuvants, etc., which, while necessary for the preparation of a pharmaceutical composition, do not or do not significantly contribute to the pharmacological activity.
- pharmaceutical composition as used herein includes in particular peroral dosage forms, for example solid, semi-liquid or liquid compositions for oral administration In a preferred embodiment, the composition is in the form of a tablet, in particular a lozenge.
- solid oral dosage forms such as powder or capsules.
- limited additions of magnesium stearate or calcium behenate can be used as lubricant and of starch as disintegrant.
- aqueous lactose solution, ethanol and suitable concentrations of starch pastes may be used.
- Common excipients for preparing a throat tablet include, for example, sorbitol (E 420), talc, sucrose fatty acid esters, saccharin sodium dihydrate, mint oil, povidone 25, and carmellose sodium.
- the pharmaceutical composition of the present invention may contain parenteralia, i. liquid dilutions for injection, as well as liquid liniments and ointments, suppositories, eye drops, nose drops.
- the composition is used to treat an infection caused by rhinoviruses, influenza viruses, and / or pneumoviruses.
- the pharmaceutical composition finds use in a method of treating a viral infection, wherein the viral infection is by HRV14 (human rhinovirus type 14), RSV (human respiratory syncytial virus), and / or H1N1 (influenza A virus H1N1) is caused.
- HRV14 human rhinovirus type 14
- RSV human respiratory syncytial virus
- H1N1 influenza A virus H1N1
- a single dose of the pharmaceutical composition contains about 0.5 mg of tyrothricin, about 1.0 mg of benzalkonium chloride and / or about 1.5 mg of benzocaine, and one or more pharmaceutically acceptable excipients.
- the term "approximately” in this context means a range of ⁇ 50%, preferably ⁇ 20%, most preferably ⁇ 10%, based on the active substance indicated above.
- the pharmaceutical composition of the present invention is administered in a daily dose of about 2-4 mg of tyrothricin, 4-8 mg of benzalkonium chloride and 6-12 mg of benzocaine.
- Viruses and bacteria are the causative agents of very common acute pharyngitis.
- This disease also known as pharyngeal catarrh, is an inflammation of the pharyngeal mucosa and underlying pharyngeal structures, accompanied by the typical symptoms of sore throat, scratching, burning, dryness in the throat and redness of the pharyngeal mucosa (1).
- acute pharyngitis requires symptomatic treatment to alleviate the pain.
- Antibiotic therapy is less frequently indicated and should only be used in 10-15% of patients with streptococcal pharyngitis (1-3), or in cases where long-term effects such as haemorrhagic fever are to be prevented.
- Throat painkillers such as Dorithricin ® have repeatedly proven clinically useful in symptomatic treatment (4).
- the combination of the antibacterial and analgesic active ingredients tyrothricin, benzalkonium chloride and benzocaine effectively reduces typical pharyngitis symptoms (4).
- Soluble Dorithricin ® tablets were tested in various dilution stages for viruses that cause respiratory infections in humans.
- One tablet contains tyrothricin 0.5 mg, benzalkonium chloride 1.0 mg, and benzocaine 1.5 mg.
- a tablet of Dorithricin ® was first pulverized, then mixed with 1 ml of dimethyl sulfoxide (DMSO) dissolved with distilled water, diluted to 1: 100, and sterile filtered (0.45 ⁇ filter). From the filtrate adjusted to pH 7.4 dilution series were prepared by means of complete nutrient medium in log2 or log10 stages.
- the solvent (DMSO) prepared according to the procedure described was used as the solvent control.
- test solutions were subjected to a vitality test in the cell culture in a first step.
- test solutions were added in all dilution stages and the solvent control to growing virus-sensitive HeLa, MDCK and HEp-2 cells and for a total of
- MTT 4,5-dimethylthiazol-2-y
- the optical density of the cell culture supernatants was determined photometrically at a wavelength of 570 nm. A higher optical density indicates a higher number of vital cells.
- a possible change in cell morphology was assessed microscopically on day 3 (HeLa, MDCK) and day 6 (HEp-2) after substance addition.
- OD values of the test sample batches were normalized to the OD values of the untreated controls defined as 100% vitality and reported as percentages.
- IC 50 mean inhibitory concentration across several parallel samples in dose response curves of the test samples could be determined, up to the concentration, which had no test substance-related impairment of cell vitality and thus suitable for use in the antiviral tests.
- the antiviral activity was tested against HRV14, FluA and RSV.
- the virus-sensitive cells were infected with the corresponding viruses in a mean infection dose (MOI) between 0.0004 and 0.0008 (HeLa with HRV14, MDCK with FluA, HEp-2 with RSV).
- MOI mean infection dose
- the virus-infected cells were treated 1 h after infection with the test solutions in physiological substance concentrations in the semipermeable agarose supernatant.
- test solutions were used with drug concentrations corresponding to the dilution of 1: 400 and higher of a Dorithricin ® tablet (Table 1). At these concentrations of active substance, no vitality-reducing effects on the HeLa, MDCK and HEp2 cells used could be detected in the vitality test.
- the 1: 100 and 1: 400 diluted Dorithricin ® drug combination exhibited significant antiviral activity and markedly reduced the plaques of RNA viruses HRV14, HlNl and RSV by 97% and 68%, 53% and 74, respectively %.
- This effect on PIa formation decreased with increasing dilution. Only at high dilutions was an effect no longer detectable: with HRV14 from 1: 3200, with RSV from 1: 6400 and with HlNl from 1: 64000.
- the relative inhibitory effect depending on the Dorithricin ® -Verkowsgrad is shown in Figure 1.
- the ribavirin (RIBA) used for the control produced a 5.3% viruspiaque reduction for HRV14 (RIBA 10 ⁇ g / ml), 96% for FluA (RIBA 3 ⁇ g / ml) and 97% for RSV (RIBA 1 ⁇ g) / ml).
- the pharmaceutical composition of the present invention additionally exhibits pronounced, dose-dependent and synergistic antiviral properties against the viruses RSV, HRV14 and H1N1.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15185764 | 2015-09-17 | ||
PCT/EP2016/071944 WO2017046312A1 (en) | 2015-09-17 | 2016-09-16 | Composition having antiviral effect |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3349741A1 true EP3349741A1 (en) | 2018-07-25 |
Family
ID=54151132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16767247.6A Withdrawn EP3349741A1 (en) | 2015-09-17 | 2016-09-16 | Composition having antiviral effect |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3349741A1 (en) |
AR (1) | AR106057A1 (en) |
DE (1) | DE202016008745U1 (en) |
EA (1) | EA039000B1 (en) |
UA (1) | UA123054C2 (en) |
WO (1) | WO2017046312A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021198504A1 (en) * | 2020-04-02 | 2021-10-07 | Inflamed Pharma Gmbh | Active substances for medical use |
LU101724B1 (en) * | 2020-04-02 | 2021-10-04 | Inflamed Pharma Gmbh | Active ingredients for medical use |
EP4091608B1 (en) * | 2021-05-21 | 2024-04-17 | Medice Arzneimittel Pütter GmbH & Co. KG | Composition with antiviral effect |
EP4275681A1 (en) * | 2022-05-10 | 2023-11-15 | inflamed pharma GmbH | Active compounds for medical use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19823319A1 (en) * | 1998-05-26 | 1999-12-02 | Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg | Topical drug for the treatment of viral infections |
DE19823318A1 (en) * | 1998-05-26 | 1999-12-02 | Karl Engelhard, Fabrik Pharm.- Praeparate Gmbh & Co. Kg | Use of a drug containing tyrothricin to treat viral infections |
-
2016
- 2016-09-16 UA UAA201803866A patent/UA123054C2/en unknown
- 2016-09-16 AR ARP160102836A patent/AR106057A1/en unknown
- 2016-09-16 EP EP16767247.6A patent/EP3349741A1/en not_active Withdrawn
- 2016-09-16 DE DE202016008745.3U patent/DE202016008745U1/en active Active
- 2016-09-16 EA EA201890653A patent/EA039000B1/en unknown
- 2016-09-16 WO PCT/EP2016/071944 patent/WO2017046312A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EA039000B1 (en) | 2021-11-19 |
AR106057A1 (en) | 2017-12-06 |
DE202016008745U1 (en) | 2019-06-21 |
UA123054C2 (en) | 2021-02-10 |
WO2017046312A1 (en) | 2017-03-23 |
EA201890653A1 (en) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60318237T2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVONOIDS AND MENTHOL | |
DE69837474T2 (en) | Antimicrobial Prevention and Treatment of AIDS and Other Infectious Diseases | |
WO2017046312A1 (en) | Composition having antiviral effect | |
DE112013001457T5 (en) | Transdermal application system | |
CH660969A5 (en) | USE OF THIADIAZINE COMPOUNDS. | |
EP0864579B1 (en) | Bismuth salts of moenomycin-like antibiotics, preparation, use and pharmaceuticals containing such salts | |
EP0655249A1 (en) | Moenomycin as a medicament for the treatment of stomach ulcer | |
EP3352763B1 (en) | Substance for prophylaxis and treatment of infections by influenza viruses | |
DE4300969C2 (en) | Use of Malotilat to accelerate wound healing in case of skin burns | |
DE60216292T2 (en) | CALCIUM TRIFLUORACETATE WITH CYTOTOXIC EFFECT | |
EP3013343B1 (en) | Antivirally active pharmaceutical composition | |
Susilawati et al. | Activity of Karehau (Callicarpa longifolia Lamk.) leaves ethanolic extract as a wound healing | |
EP0403575B1 (en) | Acyl carnitine for the treatment and prevention of virus infections | |
WO2011101113A1 (en) | Pharmaceutical comprising myramistin | |
DE1917283B2 (en) | Manufacture of antimicrobial preparations | |
DE2250032A1 (en) | MEDICINAL PRODUCTS BASED ON LYSINE DERIVATIVES FOR COMBATING LEUCOPENIA AND ANOMALIES OF WHITE BLOOD CELLS OF DIFFERENT AETIOLOGY | |
EP1001756A1 (en) | Synergistically acting compositions for selectively combating tumor tissue | |
DE3141970A1 (en) | MEDICINES FOR TREATING DISEASES GENERATED BY THE VIRUS OF THE HERPES GROUP | |
DE2221281C3 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects | |
DE202005014460U1 (en) | Tablet, useful for treating and/or preventing infections caused by influenza, comprises a plant extract of the genus Cistus | |
DE19828596A1 (en) | Use of polyvalent bacteriophages | |
DE69922808T2 (en) | Antiviral compositions containing yohimbine as a therapeutic agent | |
DE60201022T2 (en) | ANTIBIOTIC PHARMACEUTICAL FORMULATION WITH LYSERGOL FOR GAINING EFFICACY AND TREATMENT METHOD | |
DE102004008375B4 (en) | Use of physiologically acceptable ascorbate compounds in combination with a sympathomimetic as a local therapeutic agent for mucous membranes of the respiratory tract | |
CH719229A1 (en) | Composition for the prevention and/or treatment and/or containment of the further spread of viral zoonoses, including SARS-CoV-2 and its variants. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180411 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190814 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200225 |